

E1
I exhibits the same conformation as an L1 major capsid protein expressed on the surface of intact human papillomavirus virions
~~intact, native human papillomavirus virions.~~

E2
J 12. (Thrice Amended) A vaccine for the prevention of papillomavirus
J infection, said vaccine comprising at least one [PV type of] recombinantly produced human
I papillomavirus (PV) L1 protein, ~~or antigenic fragment thereof~~, which protein ~~or antigenic~~
~~fragment~~ [is capable of reproducing] reproduces the antigenicity and exhibits the same
conformation as [the] an L1 major capsid protein expressed on the surface of intact
~~intact, native~~
human papillomavirus virions.

E3
J 19. (Twice Amended) A method for protecting [an animal] a human
J against a papillomavirus infection, said method comprising administering a therapeutically
I effective amount of a vaccine, wherein said vaccine comprises at least one [PV type of]
isolated
recombinantly produced human papillomavirus (PV) L1 protein ~~or antigenic fragment~~
~~thereof~~, [which] wherein said protein ~~or antigenic fragment~~ [is capable of reproducing]
reproduces the antigenicity and exhibits the same conformation as [the] an L1 major capsid
protein expressed on the surface of intact
~~intact, native~~ human papillomavirus virions.

Kindly add the following claims:

E4
J --50. A vaccine for the prevention of human papillomavirus infection, said
J vaccine consisting essentially of at least one isolated recombinant papillomavirus (PV) L1 protein, ~~or~~
~~antigenic fragment thereof~~, which protein ~~or antigenic fragment~~ reproduces the antigenicity

Serial No. 08/216,506

I and exhibits the same conformation as an L1 major capsid protein expressed on the surface of ~~intact, native~~ ^{intact} human papillomavirus virions.
^

E4 51. The vaccine of Claim 50, wherein said human papillomavirus is selected from the group consisting of HPV 1, 2, 3a, 4, 5, 6b, 7, 8, 9, 10, 11a, 12, 13, 16 and 18.

52. The vaccine of Claim 50 wherein the human papillomavirus is either HPV-6 or HPV-11a.

53. A method for protecting a human against a papillomavirus infection, said method comprising administering a therapeutically effective amount of a vaccine according to Claim 50.

54. A method for protecting a human against a human papillomavirus infection, comprising administering to a human subject a therapeutically effective amount of a vaccine according to Claim 51.

55. A method for protecting a human against a human papillomavirus infection, comprising administering to a human subject a therapeutically effective amount of a vaccine according to Claim 52.